A Study of Standard Of Care Versus Radio Ablation in Early Stage HCC

This Phase II Prospective, parallel and open-label randomised control trial will investigate whether a radiotherapy technique (called SABR) can treat early stage liver cancer more effectively than current treatments which use heating probes directly inserted into the tumour or chemotherapy or radioactive particles injected into the blood supply of the tumour. Investigators hypothesize SABR will result in higher rates of freedom from local progression (FFLP) at 2 years compared to percutaneous thermal ablation ± TACE or transarterial therapies (TACE/TARE).The study will also look at other important outcomes such as progression free survival, overall survival, side effects, quality of life and people's experiences of their treatment.

NCT Number	NCT07628751
Lead Sponsor	University Health Network, Toronto Collaborators: Trans Tasman Radiation Oncology Group, Australasian Gastro-Intestinal Trials Group
Conditions	Early Hepatocellular Carcinoma
Enrollment	218 participants
Start Date	2026-05-11
Primary Completion	2032-04-01 (estimated)
Study Completion	2032-04-01 (estimated)
Updated on ClinicalTrials.gov	2026-06-05